Gejo SR 500 Tablet contains Metformin 500 mg, an oral antihyperglycemic agent used primarily in the management of type 2 diabetes mellitus. Metformin belongs to the biguanide class and exerts its effect by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. This multifaceted mechanism helps to achieve better glycemic control without causing significant hypoglycemia when used as monotherapy. Gejo SR 500 is formulated as a sustained-release tablet, allowing for a gradual release of the active ingredient, which enhances patient compliance by reducing dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release formulations. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, especially in overweight patients or those with insulin resistance. The medication should be used cautiously in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia or lactic acidosis. Regular monitoring of renal function and blood glucose levels is recommended during therapy. Gejo SR 500 should be taken with meals to reduce gastrointestinal discomfort, and patients are advised to maintain lifestyle modifications alongside pharmacotherapy for optimal outcomes.